Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients.
One hundred five patients with Stage III or IV epithelial ovarian cancer whose disease had persisted or recurred after primary surgery and first-line chemotherapy were given tamoxifen (20 mg orally twice daily) and evaluated for response. Eighteen percent of the patients responded: 10% demonstrated a complete response (CR) and 8% showed a partial response (PR). Thirty-eight percent of the patients had short-term disease stabilization. CR had a median duration of 7.5 months, with the longest lasting 17 months. For patients with PR or stable disease, the median duration of response was 3 months (maximum duration, 9 months). When estrogen receptors of tumor tissue from patients demonstrating CR were evaluated, eight of nine (89%) had elevated estrogen receptor levels. This contrasts with patients who had stable or progressive disease as only 59% of them had measurable estrogen receptors (P = 0.16).
Hatch
K D
KD
Department of Obstetrics and Gynecology, University of Arizona Health Sciences Center, College of Medicine, Tucson.
Beecham
J B
JB
Blessing
J A
JA
Creasman
W T
WT
D002277:Carcinoma / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D009363:Neoplasm Proteins / Q000032:analysis; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D010750:Phosphoproteins / Q000032:analysis; D011446:Prospective Studies; D011960:Receptors, Estrogen / Q000032:analysis; D012074:Remission Induction; D013629:Tamoxifen / Q000627:therapeutic use*
D009363:Neoplasm Proteins; D010750:Phosphoproteins; D011960:Receptors, Estrogen; D013629:Tamoxifen